Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas (original) (raw)
Related papers
18F-FDG PET-TC con doppio tempo di acquisizione nella identificazione delle lesioni mammarie
Purpose. The authors sought to evaluate whether the reacquisition of images 3 h after administration of radiotracer improves the sensitivity of fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography ([ 18 F]-FDG PET/CT) in patients with suspicious breast lesions. Materials and methods. Forty-eight patients with 59 breast lesions underwent an [ 18 F]-FDG PET/CT study in the prone position with a dual-time-point acquisition performed in the early phase 1 h after FDG administration (PET-1) and in the delayed phase 3 h after FDG administration (PET-2). Both examinations were evaluated qualitatively and semiquantitatively with calculation of the mean percentage variation of the standard uptake values (Δ% SUV max ) between PET-1 and PET-2. All lesions with an SUV max ≥2.5 at PET-1 or a reduction in SUV between PET-1 and PET-2 were considered benign. The definitive histopathological diagnosis was available for all patients included in the study. Results. The dual-time-point acquisition of [ 18 F]-FDG PET/CT displayed an accuracy of 85% for lesions with an SUV max ≥2.5 and/or positive Δ% SUV max , with sensitivity and specificity values of 81% and 100% compared with 69%, 63% (both p<0.001) and 100% (p=n.s.), respectively, for the single-time-point acquisition. Malignant lesions showed an increase in FDG uptake between PET-1 and PET-2, with a Δ% SUV max of 10±7 (p<0.04). In contrast,
Atención Familiar, 2021
Objetivo: estimar la frecuencia y describir las características epidemiológicas, radiológicas e histopatológicas de mujeres con cáncer de mama. Métodos: estudio transversal en 2560 mujeres mayores de 25 años que acudieron a toma de mastografía durante el año 2018. Se describió la clasificación de bi-rads. Se revisaron los expedientes clínicos de las pacientes positivas a cáncer y se recabó información que incluía características epidemiológicas, resultado de estudio de mastografía e histopatológico. Los datos obtenidos fueron analizados en el programa Excel, se estudiaron las frecuencias y los porcentajes. Resultados: la frecuencia de cáncer de mama fue de 2.65% (68/2560). 60% tenía de 50 a 69 años de edad, 59%, obesidad y 47%, antecedente familiar de cáncer de mama. De acuerdo con la clasificación bi-rads, 3% fue B3, 45% fue B4, 49%, B5 y 3%, B6. Respecto al reporte histopatológico, 83% correspondió a carcinoma ductal infiltrante. Conclusiones: en pacientes con cáncer de mama, la e...
Criteria for appropriate use of positron emission tomography with FDG (FDG-PET) in breast cancer
This document should be cited as / Il presente documento deve essere citato come Ballini L, Vignatelli L, Negro A, Minozzi S, Maltoni S, Longo G. Criteria for appropriate use of positron emission tomography with FDG (FDG-PET) in breast cancer. Dossier 207 -Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna. 2011. La collana Dossier è curata dal Sistema comunicazione, documentazione, formazione dell'Agenzia sanitaria e sociale regionale dell'Emilia-Romagna responsabile Marco Biocca redazione e impaginazione Federica Sarti Stampa Regione Emilia-Romagna, Bologna, maggio 2011 Copia del volume può essere richiesta a Federica Sarti -Agenzia sanitaria e sociale regionale dell'Emilia-Romagna -Sistema CDF oppure può essere scaricata dal sito Internet http://asr.regione.emilia-romagna.it/wcm/asr/collana\_dossier/doss207.htm Chiunque è autorizzato per fini informativi, di studio o didattici, a utilizzare e duplicare i contenuti di questa pubblicazione, purché sia citata la fonte.
A systematic review of FDG-PET in breast cancer
Medical Oncology, 2010
Objetive To assess the safety and efficacy of FDG-PET in breast cancer in the diagnostic of primary tumours, lymph node staging, the detection of recurrent disease/metastases, and the assessment of chemotherapy treatment. Methods A systematic review was undertaken. A search was made for primary studies, other systematic reviews, and health technology assessment reports in different databases. Results A total of 73 reports were included. FDG-PET does not appear to be sufficiently accurate to be used in isolation for ruling out the presence of a primary tumour. In lymph gland staging, FDG-PET does not appear to be accurate enough to detect occult axillary metastases or micrometastases (sensitivity 20 and 50%, respectively); sentinel node biopsy is required for confirmation. In the detection of bone metastases, FDG-PET should be complemented with other tests such as bone gammagraphy or SPECT. The assessment of response to chemotherapy, there seems to be no uniform criterion for establishing a standardized uptake value (SUV) for FDG that would allow responders and non-responders to be distinguished. Conclusions FDG-PET is insufficiently sensitive to rule out small primary tumours. Due to the high number of false positives returned, it cannot replace axillary dissection in axillary lymph gland staging. A complete biochemical response identified by FDG-PET should not be relied upon to mean an absence of disease since the technique cannot detect residual microscopic elements.
The Eurasian Journal of Medicine
Objective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Materials and Methods: Fifty-one LABC patients who received NAC in our center between 2011 and 2015 were retrospectively analyzed. Basal PET/CT was performed in all the patients before NAC. The SUV max levels and demographical and histopathological results were compared. The relationship between the SUV max values after NAC and pathological responses were evaluated. Results: The mean age of the patients was 49 (32-69) years. PET/CT performed after NAC showed complete response in 20 patients (39.2%), partial response in 28 patients (54.9%), stable disease in 2 patients (3.9%), and progressive disease in 1 patient (2%). There was no significant difference between the mean SUV max values of the patients according to age (>50 and ≤50 years), menopausal status, tumor localization, clinical stage, and grade. The mean SUV max value was higher in the triple-negative group than those in the HER2 positive and luminal groups. There was a significant difference in the SUV max values between the group that achieved pCR after NAC and the group that could not achieve pCR (SUV max value for breast 2.92 vs. 0.30; p=0.01; SUV max value for axilla 1.5 vs. 0.0, p=0.02). Conclusion: The SUV max values are independent of demographical features. There was a significant relationship between the pCR and SUV max values after NAC. PET/CT could be useful in the evaluation of patients to predict the biological characteristics of tumors.
Contribution of 18F-FDG PET/CT in occult breast carcinoma
2021
Early detection of primary lesion with isolated axillary lymph node metastasis without any clinical or radiological evidence of tumour is still a pending issue. It is important to offer these patients a better management and survival. The definition of occult breast carcinoma is redefined as radiological diagnostic techniques progress. We emphasize the contribution of whole-body fluorine-18 fluorodeoxyglucose positron emission tomography associated with computed tomography for staging, surgical approach and adjuvant treatments recommendations for these patients. Resumen La detección precoz de la lesión primaria en casos de metástasis aisladas de ganglios linfáticos axilares, sin evidencia clínica ni radiológica de tumor, sigue siendo una cuestión pendiente de resolver. Sin embargo, es importante para ofrecer a estos pacientes un mejor manejo y mayor supervivencia. La definición de carcinoma oculto de mama se redefine a medida que avanzan las técnicas radiológicas de imagen diagnósti...
The Eurasian Journal of Medicine, 2018
Objective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Materials and Methods: Fifty-one LABC patients who received NAC in our center between 2011 and 2015 were retrospectively analyzed. Basal PET/CT was performed in all the patients before NAC. The SUV max levels and demographical and histopathological results were compared. The relationship between the SUV max values after NAC and pathological responses were evaluated. Results: The mean age of the patients was 49 (32-69) years. PET/CT performed after NAC showed complete response in 20 patients (39.2%), partial response in 28 patients (54.9%), stable disease in 2 patients (3.9%), and progressive disease in 1 patient (2%). There was no significant difference between the mean SUV max values of the patients according to age (>50 and ≤50 years), menopausal status, tumor localization, clinical stage, and grade. The mean SUV max value was higher in the triple-negative group than those in the HER2 positive and luminal groups. There was a significant difference in the SUV max values between the group that achieved pCR after NAC and the group that could not achieve pCR (SUV max value for breast 2.92 vs. 0.30; p=0.01; SUV max value for axilla 1.5 vs. 0.0, p=0.02). Conclusion: The SUV max values are independent of demographical features. There was a significant relationship between the pCR and SUV max values after NAC. PET/CT could be useful in the evaluation of patients to predict the biological characteristics of tumors.
Valor da PET/CT na abordagem do câncer de cabeça e pescoço
Radiologia Brasileira, 2012
OBJETIVO: Avaliar a PET/CT na abordagem de pacientes com câncer de cabeça e pescoço. MATERIAIS E MÉTODOS: Estudo retrospectivo de 63 prontuários e exames de PET/CT de pacientes com câncer de cabeça e pescoço. RESULTADOS: Foram encontradas alterações em 76% dos exames. Destes, 7 (11%) foram considerados falso-positivos, com SUV < 5,0. A PET/CT mostrou-se negativa em 15 situações (24%). Dos 14 casos nos quais se utilizou o exame para estadiamento, em 3 (22%) houve aumento no estadiamento. CONCLUSÃO: A PET/CT mostra-se como exame de potencial valor na rotina de avaliação de pacientes com câncer de cabeça e pescoço, entretanto, necessitamos de maior número de casos para definirmos protocolo de uso.